Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response (pCR) rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P) versus trastuzumab emtansine (T-DM1) plus pertuzumab (T-DM1+P).Neoadjuvant TCH+P achieved a superior pCR rate compared with T-DM1+P and was associated with a higher breast-conserving-surgery rate.

ICE announced on 21 December 2016 that pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)‑positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. 

In the neoadjuvant treatment of HER2-positive BC, the KRISTINE trial compared six cycles of T‑DM1 plus pertuzumab with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCPH) [11]. Patients receiving TCPH had a significantly higher pCR rate (55.7% vs. 44.4%, p = 0.0155) and this effect was even more pronounced in non-luminal HER2-positive tumors. Toxicity rates, on the other hand, were higher in the TCPH arm as well

Hurvitz SA, Martin M, Symmans WF, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). J Clin Oncol 34, 2016 (suppl; abstr 500).
Deborah J.L. Wong and Sara A. Hurvitz, Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.Ann Transl Med. 2014 Dec; 2(12): 122.
NCCN, Breast Cancer 2017

Hurvitz SA, Martin M, Symmans WF, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). J Clin Oncol. 2016;34(suppl):abstr 500.

https://www.esmo.org/Oncology-News/NICE-Recommends-Pertuzumab-for-the-Neoadjuvant-Treatment-of-HER2-positive-Breast-Cancer, Accessed 7/17/19